Latest news with #SunPharmaceuticals
&w=3840&q=100)
Business Standard
14-07-2025
- Business
- Business Standard
Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp
Sun Pharmaceuticals on Monday announced the launch of hair loss drug Leqselvi (deuruxolitinib) in the United States (US) market for the treatment of alopecia areata, a condition in which the immune system attacks hair follicles, leading to hair loss on the scalp as well as other parts of the body. The announcement came after the Mumbai-based pharma major inked a settlement pact with US-based Incyte Corporation regarding the hair loss drug. Incyte had earlier accused Sun Pharma of patent infringement. Under the terms of the agreement, the parties will seek dismissal of the pending Leqselvi litigation in the United States District Court for the District of New Jersey. 'Incyte has also granted Sun a limited and non-exclusive licence to US patent numbers 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-haematology-oncology indications including alopecia areata, in the US,' the company said in a regulatory filing on the exchanges. The Mumbai-based pharma major will also pay Incyte an undisclosed upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and licence. Deuruxolitinib is expected to go off-patent in the financial year 2025–26 (FY26). The launch adds Leqselvi to Sun Pharma's innovative therapies portfolio, which saw sales of $1,216 million in FY25, according to Sun Pharma's investor presentation for the year. According to a Reuters report, Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun Pharma's key US market. Commenting on the launch, Sun Pharma America CEO Richard Ascroft said the launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them. 'As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community,' he added. The announcement was made post market hours. On Monday, Sun Pharma's share rose marginally by 0.57 per cent, ending the day's trade at ₹1,682.05 apiece on the Bombay Stock Exchange (BSE).
Time of India
04-07-2025
- Health
- Time of India
Hassan heart attack death cases: India's top drugmakers rally behind Covid vaccines
Leading drugmakers on Thursday rallied in support of Covid vaccines , using various social media platforms, amid a series of deaths in Karnataka's Hassan district due to heart attacks. Dilip Shanghvi, chairman and managing director at Sun Pharmaceuticals said in a post on LinkedIn, 'The deaths of multiple young individuals in one district of Karnataka due to cardiac ailments are unfortunate. While this appears to be specific to the district, linking it to the Covid-19 vaccine without any scientific evidence is "incorrect and misleading". "India's vaccine approval process is rigorous and science-driven, and we must continue to have confidence in it. The vaccine has been administered to millions across the country. If there were a connection, we would have seen similar incidents in many other places — which is not the case. The State health authorities should thoroughly investigate the situation to determine the cause,' Sanghavi said. Sorting to allay the apprehensions, Pankaj Patel, chairman, Zydus Lifesciences , which also manufactures Covid DNA vaccine, said in a post on X, 'There are other multiple reasons like age, environmental factors, genetics, lifestyle etc, that could be the leading cause of heart attacks in people. Several scientific studies globally and in India have conclusively shown that the risk of heart attack or myocarditis is greater after SARS-CoV-2 infection. #Vaccines save lives.' Appreciating the vaccination programme, Patel said, "the massive vaccination programme in our country during the peak of Covid phase saved millions of people and families. In fact a study published in Lancet estimated that India averted almost 3.4 million deaths due to vaccination in the year 2021," he said. Live Events Satish Reddy, chairman, Dr Reddy's Laboratories, wrote, 'India-made vaccines are by WHO and used worldwide. They helped end polio and fight Covid. At a time when India is seen as a vaccine leader, let's build trust in science, not doubt it. Public health must stay above politics.' A post on X attributed to Samir Mehta, executive chairman, Torrent Pharma said, 'India has earned global recognition as the Pharmacy of the World, supplying safe and effective vaccines to over 90 countries…Let's not allow misinformation to erode trust in science or the integrity of India's healthcare ecosystem.' Responding to rising concerns over the sudden deaths of more than 20 people in Hassan district, the Karnataka health department formed an expert committee to probe a possible link to Covid vaccines. However, support came pouring in for Covid vaccines. The Indian Vaccine Manufacturers Association said Covid-19 vaccines were developed and manufactured in the country with the highest safety and quality standards. Assuring about the safety of these vaccines, Dr/ G.V.J.A. Harshavardhan, director general at the association said the approvals were based on extensive evaluation in preclinical studies and human clinical trials with positive results on safety, efficacy, and immunogenicity of the vaccines. 'Patient safety and product quality are always prioritised during the vaccine development and its manufacture,' he said in a statement. He said prior to releasing the vaccines, they were tested extensively for safety by the manufacturers and are also provided batch release certification by the Central Drugs Laboratory (CDL) of the Ministry of Health and Family Welfare. Sudarshan Jain, secretary general, Indian Pharmaceutical Alliance (IPA) said during the pandemic, vaccines played a crucial role, and India consistently supplied medicines and vaccines across the world. "These vaccines have been well documented and rigorously tested as per regulatory processes. Misinformation and distortion of facts endanger public health and undermine the trust built on science and patient care globally".
Time of India
30-06-2025
- Business
- Time of India
Analysts betting on these four pharma, hospital stocks due to Indian healthcare sector's strong growth prospects
Pharma segment outlook Hospital segment outlook Sun Pharmaceuticals Gained market share in the domestic formulations segment in Q4 FY25, with 14% year-on-year revenue growth driven by higher volumes and new product launches. Missed Reuters-Refinitiv estimates, with revenue falling short by 3.3% and net profit by 13.3%, primarily due to weaker sales in the US and Rest of the World (RoW) markets. Domestic growth outlook supported by upcoming launches in anti-diabetes and weight management therapies; US growth to come from existing product sales. Plans to invest $100 million in specialty portfolio (dermatology and oncology) for product launches, promotions, and field force expansion. Motilal Oswal remains bullish, citing Sun's push for differentiated offerings in regulated markets to drive future earnings. Reported in-line revenue growth in Q4 FY25, while net profit beat Reuters-Refinitiv estimates by 19.1%, aided by higher other income and lower finance costs. India business drove revenue growth and is expected to remain strong, supported by its innovative portfolio and therapies like respiratory and urology. Recent US approvals for cancer drugs (Abraxane, Nilotinib) and upcoming respiratory launches over the next 12–18 months are expected to stabilise US performance. Management is focused on boosting manufacturing capacity, investing in R&D for differentiated products, and exploring inorganic growth opportunities. According to Antique Stock Broking, Cipla is entering a structural growth phase in the US generics market, driven by continued investment in complex generics, respiratory, and peptide segments. Apollo Hospitals Enterprise An integrated healthcare services provider, the company reported in-line revenue and a 5% net profit beat versus Reuters-Refinitiv estimates in Q4 FY25, supported by higher other income and a lower tax rate; the hospital segment delivered a mixed performance.. ARPOB rose 5% y-o-y driven by higher patient realisation; expected to improve further with better payer mix and rising surgical volumes. Plans to add 3,577 beds over 3-4 years; margin impact from new additions to be offset by cost optimisation. Pharmacy business outlook supported by growing GMV, new store openings, and efficiency measures. Diagnostics segment expected to revive, led by growth in primary and secondary clinics. Motilal Oswal sees positives in bed additions, better productivity at existing facilities, reduced pharmacy losses, and a likely turnaround in diagnostics profitability. Fortis Healthcare Posted in-line revenue and an 11.3% net profit beat in Q4 FY25, driven by higher ARPOB and better occupancy. Hospital revenue grew 14% y-o-y; diagnostics rose 3%. Management expects 14-15% hospital growth in 2025-26 and 24-25% diagnostics margins over 2–3 years. Expansion underway via greenfield projects and acquisitions (Manesar, Jalandhar). Elara Capital raised 2026-27 earnings estimates on strong growth guidance. The healthcare sector—including pharmaceuticals and hospitals— delivered a strong performance in the March 2025 quarter. The pharmaceutical segment benefited from increased demand in chronic therapies within the domestic formulations market, along with steady growth in the US generics business. Meanwhile, the hospitals segment was bolstered by expanded bed capacity and robust growth in average revenue per occupied bed (ARPOB).According to Reuters-Refinitiv data, 129 pharmaceutical companies—including those in biotechnology and life sciences— reported an aggregate revenue growth of 11.5% year-on-year (y-o-y) in the March 2025 quarter. Meanwhile, 26 healthcare providers, including diagnostic firms , recorded a 15.1% year-on-year revenue analysis includes only companies with a market capitalisation above `100 crore. In comparison, Nifty 500 companies posted a lower aggregate revenue growth of 6% healthcare sector performed well in 2024 amid global economic uncertainty driven by geopolitical tensions, trade disruptions, and interest rate volatility. The Nifty Healthcare Index emerged as the second-best performer among the 16 sectoral indices on the National Stock Exchange (NSE) over the past the sector's performance—particularly pharmaceuticals—has moderated in recent months due to concerns over the loss of exclusivity for generic Revlimid (gRevlimid), a cancer drug, which is expected to intensify competition and pressure prices and margins. Additionally, nearterm growth challenges in the domestic formulations segment have weighed on the sector the recent announcement by US President Donald Trump regarding potential tariffs on pharmaceutical imports has dampened investor sentiment. Indian pharmaceutical companies, which earn a significant share of their revenue from US exports, are expected to feel the impact. As a result, the Nifty Pharma Index has become the fourth worst-performing sectoral index on the NSE in 2025 so far, based on data as of 23 June long-term prospects of the pharmaceuticals sector remain intact. A recent Axis Securities report lists strong product pipeline in biosimilars, GLP-1 (class of drugs used to treat diabetes), and peptides (chain of amino acids used to treat diseases), stable margins, and higher contribution from chronic therapies as key growth catalysts for Indian pharmaceutical companies. Moreover, stability in price erosion, differentiated portfolio, and exposure to complex generics is expected to support the US generics concerns remain over the loss of exclusivity for gRevlimid, Indian pharmaceutical companies stand to gain from strong opportunities in the US generics market. The expiry of exclusivity is expected to accelerate generic launches, benefiting manufacturers— particularly Indian to a recent report by Antique Stock Broking, a combination of greater loss-of-exclusivity opportunities, rationalised global competition, and improved regulatory compliance is expected to drive revenue growth for Indian pharmaceutical companies through new product launches and volume gains in existing also see potential in the CDMO (contract development and manufacturing organisation) space. A BNP Paribas report highlights investor feedback suggesting that India stands to benefit as global innovators diversify supply chains away from China. However, concerns persist over high valuations in the segment and limited near-term earnings the hospital segment, factors such as the rise in lifestyle diseases, improving affordability and accessibility driven by higher disposable incomes, a significant demand-supply gap, growing medical tourism, a shift in payer mix due to increased insurance penetration, and bed capacity expansion by private players are expected to drive low healthcare spending in India compared to the world average, rising median age, and a pickup in highgrowth therapies such as cardiac and cancer care—which boost ARPOB and occupancy— are the additional growth catalysts. An IBEF report estimates the Indian hospital market to grow by 8% CAGR between 2022-23 and 2031-32 to reach $193.6 billion. Here are the four stocks (two each from the pharmaceuticals and hospitals segments) with strong analyst TAM growth (%)
Yahoo
24-06-2025
- Business
- Yahoo
Market Accelerates Amid Rising Disease Prevalence, Kinase Innovation, and Demand for Safer Treatments
The global kinase inhibitors in autoimmune diseases market is experiencing significant growth, driven by rising autoimmune disease prevalence and advancements in biotechnology, specifically in targeted therapies like JAK inhibitors. These innovations provide a precise approach to treatment, addressing the root causes of immune dysfunction and benefiting from expedited regulatory approvals. While challenges such as high costs and competition persist, heavy investments in research and clinical trials suggest sustained market growth. North America is set to lead, backed by robust healthcare infrastructure and regulatory benefits. Major players like Pfizer and Sun Pharmaceuticals are enhancing product offerings, underscoring the competitive landscape. Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Kinase Inhibitors in Autoimmune Diseases Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to offering. The global kinase inhibitors in autoimmune diseases market is currently in the growth stage of its lifecycle. With the increasing prevalence of autoimmune diseases and advancements in biotechnology, the demand for targeted therapies such as JAK inhibitors has been rising. Increasing demand for kinase inhibitors in autoimmune diseases therapies is anticipated to support the growth of the global kinase inhibitors in autoimmune diseases market during the forecast period 2025-2035. The global kinase inhibitors in autoimmune diseases market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers. These therapies offer a more specific approach to treatment, addressing the underlying causes of immune system dysfunction, which is a key driver for market expansion. The market is also benefitting from regulatory support and faster drug approvals, allowing new treatments to reach the market more quickly. However, challenges like high treatment costs, side effects, and competition from established therapies still are investing heavily in research and clinical trials to expand their drug pipelines and enhance treatment options, signaling continued market growth. As the market matures, it is expected to face increasing competition and pricing pressures, but the demand for more targeted and personalized treatments is likely to sustain its upward trajectory. North America is expected to dominate the global kinase inhibitors in autoimmune diseases market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global kinase inhibitors in autoimmune diseases market. How Can This Report Add Value to an Organization?Product/Innovation Strategy: Product launches and innovations in the global kinase inhibitors in autoimmune diseases market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Pfizer, and Sun Pharmaceuticals, have been involved in the development of therapies for kinase inhibitors in autoimmune Strategy: Enterprises led by market leaders in the global kinase inhibitors in autoimmune diseases market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the Developments Launches: In March 2025, Pfizer Korea launched Litfulo (ritlecitinib tosylate), a new Janus kinase (JAK) inhibitor, for the treatment of severe alopecia areata in adolescents and adults, thereby expanding treatment options for patients aged 12 and older in Korea. Regulatory Activities: In July 2024, The U.S. FDA approved Sun Pharmaceutical Industries Ltd.'s Leqselvi (deuruxolitinib), a JAK1 and JAK2 inhibitor, for the treatment of adults with severe alopecia areata, a chronic autoimmune disease. Demand - Drivers and Limitations The following are the drivers for the global kinase inhibitors in autoimmune diseases market: Rising Prevalence of Autoimmune Diseases Advancements in Kinase Inhibition Technology Growing Demand for Non-Immunosuppressive Therapies The global kinase inhibitors in autoimmune diseases market is expected to face some limitations, too, due to the following challenges: High Treatment Costs Limited Indication Scope Key Market Players and Competition Synopsis Pfizer Eli Lilly and Company Reistone Biopharma Incyte Corporation Bristol Myers Squibb Galapagos NV Aclaris Therapeutics Kadmon Pharmaceuticals Sanofi Ono Pharmaceutical Co. Ltd Key Topics Covered: Executive Summary1. Global Kinase Inhibitors in Autoimmune Diseases Market: Industry Outlook1.1 Market Overview and Ecosystem1.2 Market Trends1.3 Epidemiological Analysis of Autoimmune Diseases1.3.1 By Region1.4 Clinical Trials1.4.1 By Phase1.4.2 By Sponsor Type1.5 Regulatory Landscape / Compliance1.5.1 Legal Requirement and Framework in the U.S.1.5.2 Legal Requirement and Framework in the E.U.1.5.3 Legal Requirement and Framework in Asia-Pacific1.6 Market Dynamics1.6.1 Market Drivers1.6.2 Market Restraints1.6.3 Market Opportunities2. Global Kinase Inhibitors in Autoimmune Diseases Market, By Region, $Million, 2023-20352.1 North America2.1.1 Market Dynamics2.1.2 Market Sizing and Forecast2.1.2.1 North America Kinase Inhibitors in Autoimmune Diseases Market (by Country)2.1.2.1.1 U.S.2.1.2.1.2 Canada2.2 Europe2.2.1 Market Dynamics2.2.2 Market Sizing and Forecast2.2.2.1 Europe Kinase Inhibitors in Autoimmune Diseases Market (by Country)2.2.2.1.1 U.K.2.2.2.1.2 Germany2.2.2.1.3 France2.2.2.1.4 Italy2.2.2.1.5 Spain2.2.2.1.6 Rest-of-Europe2.3 Asia-Pacific2.3.1 Market Dynamics2.3.2 Market Sizing and Forecast2.3.2.1 Asia-Pacific Kinase Inhibitors in Autoimmune Diseases Market (by Country)2.3.2.1.1 Japan2.3.2.1.2 China2.3.2.1.3 India2.3.2.1.4 Rest-of-Asia-Pacific2.4 Rest-of-the-World2.4.1 Market Dynamics2.4.2 Market Size and Forecast3. Global Kinase Inhibitors in Autoimmune Diseases Market - Competitive Benchmarking and Company Profiles3.1 Competitive Landscape3.1.1 Key Strategies and Developments by Company3.1.1.1 Funding Activities3.1.1.2 Mergers and Acquisitions3.1.1.3 Regulatory Approvals3.1.1.4 Partnerships, Collaborations and Business Expansions3.1.2 Key Developments Analysis3.2 Company Profiles3.2.1 Company Overview3.2.2 Product Portfolio3.2.3 Target Customers/End Users3.2.4 Analyst View4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Economic Times
23-05-2025
- Business
- Economic Times
Sun Pharma shares in focus after Q4 profit drops 19% YoY to Rs 2,154 crore
Sun Pharma's Q4 consolidated net profit fell 19% YoY to ₹2,154 crore, despite an 8% rise in revenue to ₹12,959 crore. Sequentially, both profit and revenue declined. For FY25, net profit rose to ₹10,965 crore. The company reported exceptional charges related to a U.S. settlement. Shares slipped 0.7% amid mixed financial results. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Shares of Sun Pharmaceuticals will be in focus on Friday after the drug major reported a 19% year-on-year (YoY) decline in consolidated net profit for the March quarter to Rs 2,154 crore, compared with Rs 2,659 crore in the same period last from operations rose 8% YoY to Rs 12,959 crore, up from Rs 11,983 crore in Q4FY24. However, on a sequential basis, both profit and revenue were down. PAT declined 26% from Rs 2,913 crore reported in Q3FY25, while revenue fell 5% from Rs 13,675 crore in the previous the full financial year, net profit stood at Rs 10,965 crore versus Rs 9,610 crore in Q4FY24. Meanwhile, the revenue expanded by 8.5% to Rs 52,578 crore in Q4FY25 versus Rs 48,497 crore in the quarter company reported exceptional items worth Rs 678 crore along with an exceptional tax expense of Rs 377 crore for the year ended March 31, 2025. This includes a charge of $37.44 million (Rs 316 crore), including legal expenses of $0.7 million ( Rs 5.82 crore) in the quarter ended December 31, 2024, on the agreement of a settlement in principle on the primary financial terms, with no admission of wrongdoing in the company reported expenses of Rs 9,956 crore in the quarter under review, which was 10,349 crore in Q3FY25 and Rs 9,672 crore in the year ago period. The expenses were incurred under the heads like cost of materials consumed, purchases of stock-in-trade, employee benefit expenses and finance cost. Sun Pharma shares closed at Rs 1,720 on Thursday, down 0.7% on the BSE, even as the Sensex gained 0.79%. The stock has declined 9% year-to-date but gained 84% over the last two years. Its current market capitalisation stands at Rs 4,12,675 crore.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
